Clinical Trial Search

Primary: Phase 1b: Recommended Phase 2 Dose of LY2228820 in Combination With Gemcitabine and Carboplatin (Maximum Tolerated Dose [MTD]) — 200 milligrams (mg)

Primary: Progression Free Survival (PFS) Rate at 6 Months — 55.2 percentage of patients

Primary: Median Time to Progression — 7.2 months

Primary: Progression-free Survival at 6 Months — 40.3 percentage of participants

Primary: Overall Response Rate (ORR) — 4 participants

Primary: Objective Response Rate (ORR) — 2; 0 Participants

Primary: Tumor Response — 7; 30; 12; 6 participants

Primary: Progression-free Survival — 2.9; 5.3 months — p=0.019

Primary: Efficacy: Progression Free Survival (PFS) — 3.1; 5.6; 3.8 months — p=0.265

Primary: Tumor Response — 15.4 percentage of patients

Primary: Progression-free Survival (PFS) — 56 percentage of participants

Primary: Progression-free Survival Rate After 6 Months of Treatment on Study — 0 participants

Primary: Progression-free Survival (PFS) — 13.7; 8.4 months

Primary: PFS — 29.8 Months

Primary: Overall Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors and by Rustin's Criteria (RECIST) — 4; 5; 9; 4 Participants

Primary: Tumor Response — 16.7 percentage of patients

Primary: Overall Response Rate — .083 proportion of participants

Primary: Tumor Response Duration — 3.9; 24.1 months

Primary: Objective Tumor Response — 4; 8; 8; 32 Participants

Primary: Patients' Overall 90-Day Clinical Response as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) — 8; 18 Participants

Primary: Proportion of Patients With Complete and Partial Tumor Response — 0.26 Proportion of patients

Primary: Four Cycle Progression-free Survival Rate — 8 Participants

Primary: Incidence of Adverse Events Assessed by Common Terminology Criteria for Adverse Events — 1; 9; 20; 9 Participants

Primary: Efficacy: Progression-free Survival (PFS) — 4.3; 2.8; 5.3; 2.8 Months — p=0.0220

Primary: Objective Tumor Response — 12.2; 31.4 percentage of participants

Primary: Objective Response Rate (ORR) Investigator Assessment: % of Patients in the Group Who Achieve a Complete Response(CR) or Partial Response(PR) According to RECIST…

Primary: Objective Tumor Response Rate (Complete and Partial Response) — 6.7 percentage of participants

Primary: Objective Tumor Response — 21; 32; 17; 1 participants

Primary: Progression-free Survival (PFS) at 6-months — 28 percentage of participants

Primary: The Percentage of Patients Who Survive Progression Free for at Least 6 Months — 23 percentage of participants